title: Does the teratogenicity of isotretinoin outweigh its benefits?
authors.forename: Amy Y
authors.initials: AY
authors.lastname: Jordan
authors.forename: Lauren
authors.initials: L
authors.lastname: Parks
authors.forename: Suephy C
authors.initials: SC
authors.lastname: Chen
authors.forename: Kristen
authors.initials: K
authors.lastname: Higgins
authors.forename: Alan B
authors.initials: AB
authors.lastname: Fleischer
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000152:Acne Vulgaris / Q000188:drug therapy / Q000523:psychology; D003879:Dermatologic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000009:adverse effects* / Q000627:therapeutic use; D011247:Pregnancy; D011788:Quality of Life; D019057:Quality-Adjusted Life Years
chemical_list: D003879:Dermatologic Agents; D015474:Isotretinoin